EuroDry Non-GAAP EPS of $2.36, revenue of $19.4M (EDRY:NASDAQ)

EuroDry reported Q3 Non-GAAP EPS of $2.36 and revenue of $19.4M, a 34.9% Y/Y increase. Net income was $6.9M, reversing a $0.7M loss from the prior year, with adjusted net income at $6.7M, according to the company.

Original reporting
Published Nov 11, 2026, 1:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$EDRY
Bullish
high confidence
Mentioned
$EDRY
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$EDRYBullishMed
01

Why it matters

The earnings beat expectations and reverse a prior loss, likely prompting buying interest.

02

Market read

First‑report earnings for a micro‑cap, modest but material for traders focused on small‑cap catalysts.

03

What to watch

Cost structure and cash burn trends are not disclosed.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

EuroDry released its Q3 2026 earnings, reporting a swing to profit.

Company-level read

Ticker impact

$EDRYBullishHigh confidence
Context

Q3 Non-GAAP EPS $2.36 and revenue $19.4M, up 34.9% YoY, turning a $0.7M loss into $6.9M profit.

Expected impact

upward pressure as market prices in the profit swing.

Evidence & confidence

First‑report earnings show a material profit versus a loss a year ago, indicating improved operations.

Market effects

Shows strength in the specialty chemicals niche, may boost peers.

Limited to U.S. small‑cap investors.

Low; impact confined to niche sector.

Counterpoint

Profit may be one‑off; underlying demand could be volatile.

Key entities

  • EuroDry

    Specialty chemicals producer listed on NASDAQ.

Related articles

$EDRYMed

EuroDry Ltd. (EDRY): Financial results for 9M 2026

EuroDry Ltd. (EDRY) furnished an SEC Form 6-K — earnings release. INFORMATION CONTAINED IN THIS FORM 6-K REPORT Attached to this Report on Form 6-K as Exhibit 1 is a copy of the press release issued by EuroDry Ltd. (the “Company”) on November 11, 2026: EuroDry Ltd. Reports Results for the Quarter and Nine-Month Period Ended September 30, 2026.

$EDRYMed

Will Dry Bulk Market Strength Lead EuroDry Stock to Higher Highs?

EuroDry (EDRY) reported a 57% revenue increase to $17.7M in Q2 2026, driven by a doubling of its average TCE rate to $20,398/day. Adjusted EBITDA rose to $11.7M, and net income turned positive at $6.6M. The company benefits from strong dry-bulk market demand and favorable charter rates. Star Bulk (SBLK) and Genco Shipping (GNK) also reported significant earnings improvements due to higher rates.

$NVTMed

Louis Navellier unveils 3 under-radar stocks to buy on dips

Louis Navellier highlights three stocks to buy on dips: nVent Electric (NVT) for its $1.75B acquisition of Maverick Power, Astronics (ATRO) due to strong demand and record backlog, and Eurodry (EDRY) benefiting from elevated shipping rates. NVT expects the deal to boost revenue, ATRO reported 27% revenue growth and a 14.8% earnings surprise, while EDRY saw a 93.7% earnings surprise.

$EDRYMedAI 8/10

EuroDry (EDRY) Q2 2026 Earnings Call Transcript

EuroDry Ltd. (EDRY) reported Q2 2026 net revenues of $17.7 million, up 57% year over year, driven by higher time charter equivalent rates. Net income was $6.6 million, or $2.32 per diluted share, and adjusted EBITDA rose to $11.7 million. Management cited 100% utilization, a $98.1 million debt balance, and a 2026 annualized EBITDA outlook of $38.4 million.

$EDRYMed

EuroDry Ltd. (EDRY): Financial results for H1 2026

EuroDry Ltd. (EDRY) furnished an SEC Form 6-K — earnings release. INFORMATION CONTAINED IN THIS FORM 6-K REPORT Attached to this Report on Form 6-K as Exhibit 1 is a copy of the press release issued by EuroDry Ltd. (the “Company”) on August 6, 2026: EuroDry Ltd. Reports Results for the Quarter and Six-Month Period Ended June 30, 2026. This Repo

$INKTHigh

MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H…

MiNK Therapeutics, Inc. (INKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies November 11, 2026 & Patients with serious unmet medical need access agenT-797 through phy